Advances in PH Journal
Advances in Pulmonary Hypertension Summer 2009 (Vol 8, No 2)
- Editor's Memo
As a participant in the 4th World Symposium on Pulmonary Hypertension, held February 2008 in Dana Point, California, I was struck by several things-first was the beautiful setting.
- Guest Editor's Memo
4th World Symposium Makes History
- Advances in Pulmonary Hypertension CME Section
- Epidemiology and Classification of Pulmonary Hypertension
During the 4th World Symposium on Pulmonary Hypertension held last year in Dana Point, California, the consensus agreement of experts worldwide was to maintain the general philosophy and organization of the previous Evian and Venice classifications.
- Summary of Pulmonary Hypertension Genetics and Genomics
The 4th World Symposium on Pulmonary Hypertension convened a group of investigators to define the current state of knowledge with respect to the genetics and genomics of pulmonary arterial hypertension (PAH), and to provide suggestions for future investigations.
- Diagnosis and Assessment of Pulmonary Arterial Hypertension
The ideas regarding definition, diagnosis, and assessment of pulmonary arterial hypertension (PAH) are evolving. The importance of objective evaluation of right ventricular (RV) function is now more emphasized.
- Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension
Ernst von Romberg, a German physician, described an autopsy in 1891 as "pulmonary vascular sclerosis"; however, only with the introduction of intravenous epoprostenol in 1995 have disease-specific targeted medical therapies for pulmonary arterial hypertension (PAH) become available.
- Diagnosis, Assessment, and Treatment of Non-Pulmonary Arterial Hypertension Pulmonary Hypertension
The 4th World Symposium in Dana Point was the first among the world meetings on pulmonary hypertension (PH) that assigned a working group to address in detail the so-called nonpulmonary arterial hypertension (PAH) forms of PH; ie, those forms of PH that are seen in patients with chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), left heart disease, venous thromboembolism, and other conditions.
- Future Perspectives for the Treatment of Pulmonary Arterial Hypertension
The task presented to the Future Perspectives working group at the 4th World Symposium on Pulmonary Hypertension meeting in Dana Point was daunting: to identify what can be expected in the near future in the treatment of this complex disease process.
- CME Self-Assessment Examination
- Pulmonary Hypertension Roundtable
Discussion of the Impact of the 4th World Symposium on Pulmonary Hypertension
- Ask the Expert
What is the current status regarding exercise-induced pulmonary hypertension (PH)?
- Article Reviews
Summaries and commentaries from the section editors and invited reviewers present a clinical context for practitioners' application of the latest published research relevant to care of patients with pulmonary hypertension.
- Clinical Trials Update
In this issue, we will focus on the results of Freedom-C, which was presented in November of 2008, as well as the Walk-PHaSST study, which was stopped early in July 2009.
- PHRN Corner
I began working with pulmonary hypertension patients in 1998, when the only FDA-approved drug was Flolan. I am amazed that in a span of 11 years we now have 8 FDA-approved drugs with several more on the horizon.
- International Corner
Pulmonary Arterial Hypertension: Where Are We and Where Are We Going?
